Semaglutide May Cut Cardiovascular Risk Before Weight Loss - Medscape
In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or full dosing was achieved.
Search Group
Share To
Comments
About Screade
Screade® Inc. version 86373cf, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments